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Abstract
Background: Schema Therapy (ST) is an integrative psychotherapy based upon a cognitive schema
model which aims at identifying and changing dysfunctional schemas and modes through cognitive,
experiential and behavioral pathways. It is specifically developed for patients with personality
disorders. Its effectiveness and efficiency have been demonstrated in a few randomized controlled
trials, but ST has not been evaluated in regular mental healthcare settings. This paper describes the
study protocol of a multisite randomized 2-group design, aimed at evaluating the implementation
of outpatient schema therapy for patients with borderline personality disorder (BPD) in regular
mental healthcare and at determining the added value of therapist telephone availability outside
office hours in case of crisis.
Methods/Design: Patient outcome measures will be assessed with a semi-structured interview
and self-report measures on BPD, therapeutic alliance, quality of life, costs and general
psychopathology at baseline, 6, 12, 18 and 36 months. Intention-to-treat analyses will be executed
with survival analysis for dichotomous variables, and one-sample t-tests and ANCOVAs for
continuous variables with baseline as covariate and condition as between group factor. All tests will
be two-tailed with a significance level of 5%.
Discussion: The study will provide an answer to the question whether ST can be effectively
implemented and whether phone support by the therapist has an additional value.
Trial Registration: The Dutch Cochrane Center, NTR (TC = 1781).
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Borderline Personality Disorder (BPD) is a disabling psy-
chiatric disorder, which is characterized by substantial dis-
tress and disruptions in functioning. It has for long been
viewed as a severe and difficult to treat psychiatric condi-
tion. However, during recent years several promising
treatment possibilities have been developed. Among
them, Schema Therapy (ST) was found to be effective
regarding all aspects of BPD [1,2]. How well ST can be
delivered in regular mental healthcare practice is
unknown, but it is expected that its implementation poses
challenges.
BPD is marked by chronic instability in multiple areas
(emotional dysregulation, self-harm, impulsivity and
identity disturbance). The lifetime prevalence of BPD in
the general population is 1-2%. In psychiatric outpatient
settings 10% of the patients suffer from BPD, in psychiat-
ric inpatients settings 20% [3]. The medical and societal
costs for BPD are substantial [2,4,5]. About 10% of the
BPD patients die because of suicide [6,7].
However, recent years showed progress in the develop-
ment of treatment options [8-14] that are supported by
randomized controlled trials [1,7,15-19]. These treat-
ments demonstrated effectiveness on symptom level, as
manifested by reduced suicide attempts, fewer acts of self-
harm or hospitalizations. Although pharmacological
treatment can reduce symptoms, a Cochrane review indi-
cates that there is no convincing evidence that any medi-
cation has complete success [20]. Psychotherapy is the
necessary and primary treatment modality for BPD [21].
In a RCT which compared Schema Therapy and Transfer-
ence Focused Psychotherapy (TFP) [1] both therapies
showed a significant change in patients' personality, also
at 1-year follow up [22]. This study showed that three
years of ST and TFP proved to bring about a significant
change in patient's personality, shown by reductions in all
BPD symptoms and general psychopathologic dysfunc-
tion, increases in quality of life, and changes in associated
personality features. While both treatment conditions
showed positive results in the treatment of many aspects
of BPD, ST was superior to TFP with respect to reduction
in BPD manifestations, general psychopathologic dys-
function, and change in ST/TFP personality concepts. ST
had a recovery rate of 45.5% and a reliable change rate of
65.9% at three years, whereas the dropout rate for ST
(27%) was significantly lower than for TFP (51%). As a
result of these findings, ST is considered as an evidence
based treatment option for borderline personality disor-
der in the Multidisciplinary Dutch Guidelines on Person-
ality Disorders [23].
Based on these positive results, a study of the implemen-
tation of ST in regular mental healthcare practice was
planned. The rationale is that clinical interventions with
proven effectiveness are not necessarily implemented in
regular practice and, if implemented, treatment outcomes
are not always equally good as in the clinical trial. One of
the premises in the therapeutic approach of ST [11,13,14]
and Dialectical Behavior Therapy [8,9,17,18] is that bor-
derline patients need extra support of the therapist in
between sessions when they are in crisis or in emotional
need. For this reason patients are offered a special phone
number where they can reach their therapist outside office
hours. This personal connection between sessions is sug-
gested to help to refute the patient's beliefs that there is
nobody who really cares and can help to prevent or over-
come crisis. In a pilot study of ST crisis support in the form
of therapist phone accessibility outside office hours was
one of the most controversial topics [24] and led some
therapists to withdraw from the project. In general mental
healthcare there is much discussion about this topic
because of the financial consequences, the burden to and
responsibility of the therapist, and the possible risk of vio-
lation of boundaries. Therefore, telephone accessibility
outside office hours was perceived as an important barrier
for the successful implementation of ST in regular prac-
tice. The RCT by Giesen-Bloo et al. [1] demonstrated that
ST is a successful treatment, but it remains unknown
whether the crisis support by the therapist was crucial to
outcomes. Since the issue of crisis support outside office
hours by the therapist makes it difficult to implement ST
in regular practice and its effect has never been examined,
we decided to investigate the role of the crisis support out-
side office hours in the implementation study by ran-
domly allocating the crisis support outside office hours to
50% of the therapists.
In sum, this study will test the implementation of ST for
BPD in regular mental healthcare and will compare two
modalities: one with extra crisis support by the therapist
outside office hours and one without such telephone sup-
port. The study has three aims. First, to assess whether
patient outcomes after 1.5 years of ST will be the same
when implemented in regular practice, compared to what
was found in the RCT [1]. Since rigorous evaluations such
as RCTs always imply controlled conditions, it is unclear
to what extent their positive effects can be generalized to
regular clinical practice. Treatment effects may be more
modest outside RCTs because of different circumstances
[25-27]. The second aim will be to assess the added value
of therapist telephone availability outside office hours in
case of crisis (TTA) during the 1.5 yrs of ST. The third aim
will be to assess the problems that may arise during the
implementation process.
Methods/Design
Study Design
This study is a multicenter randomized two-group trial for
studying the added value of therapists phone support out-
side office hours. It is also a clinical evaluation of imple-Page 2 of 10
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mental healthcare treatment results with those in a rand-
omized clinical trial in academic settings. The interven-
tions and assessments will be executed between
December 2005 and August 2010.
Recruitment/Settings and locations
Mental healthcare centers
Different mental healthcare centers, covering urbanized
areas and located in various parts of the Netherlands will
be approached and invited to take part in the implemen-
tation study. Selection criteria are a) at least two therapists
on each location so that peer supervision groups can be
formed, b) therapists agree in executing the telephone
availability outside office hours and managers have to
give their permission to do so, c) both therapists and man-
agers have to agree in making the necessary time reserva-
tions for monthly supervision and weekly peer
supervision.
Patients and procedures
Patients will be recruited within the departments of the
mental healthcare centers. They can also be referred by
therapists of other mental health institutes, primary care
physicians or psychotherapists with private practices.
Patients have to be referred based on a clinical diagnosis
of BPD. At each site patients will be screened on the inclu-
sion-exclusion criteria by specialized trained research
assistants and be informed about the study. A positive
screening procedure takes two months, and this interval
serves as a patient's motivational check for undergoing
intensive psychotherapy.
If patients are willing and eligible to participate signed
informed consent will be obtained after full explanation
of the procedures and both conditions of ST at the first
assessment and before randomization. See Figure 1 for the
flowchart. Participants do not receive compensation for
screening or assessments. Participating in assessments is
obligatory to receiving the studied treatments.
Participants
Inclusion criteria
Patients (aged 18-60) are eligible to participate if their
main diagnosis is a Borderline Personality Disorder
according to the DSM-IV criteria [3]. The Structured Clin-
ical Interview for the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (SCID-II) [28,29] will
be used for assessing the diagnosis BPD. In addition, the
level of symptom severity should be ≥ 20 on the Border-
line Personality Disorder Severity Index (BPDSI-IV)
[30,31]. Co morbid axis-I and axis-II disorders are allowed
as is medication use.
Exclusion criteria
Patients are excluded from the study if they suffer from
one or more of the following disorders: a psychotic disor-
der (except short, reactive psychotic episodes), bipolar
disorder, dissociative identity disorder, antisocial person-
ality disorder, attention deficit hyperactivity disorder,
addiction of such severity that clinical detoxification is
indicated (after which entering treatment is possible),
psychiatric disorders secondary to medical conditions and
mental retardation or if they do not have sufficient com-
mand of the Dutch language necessary to participate in
the study.
Randomization
To prevent regional influences and enhance implementa-
tion TTA has to be equally spread over the different sites.
Therefore a stratified randomization procedure will be
used. The stratification procedure will be performed by a
study-independent person and will be concealed for par-
ticipating therapists, patients and researchers. Stratified
per center, 50% of the therapists will be randomly allo-
cated to the condition with extra phone support and 50%
of the therapists to the condition without extra phone
support. Each therapist will treat two patients either with
or without phone support dependent upon the randomi-
Shows the procedures in a flow chartFigure 1
Shows the procedures in a flow chart.
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Referred patients with BPD 
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• Screening in- and 
exclusion criteria 
• Informed consent 
Randomization
Allocated to intervention 
ST with phone support 
N = 30 
Allocated to intervention 
ST without phone 
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ing the informed consent form patients will be randomly
assigned to one of therapists of the participating institutes
in their regions.
Assessments
Data are collected at four points in time: at baseline (T0),
after 6 months of treatment (T1), 12 months of treatment
(T2) eighteen months of treatment (T3) and a three- year
follow-up (T4). Experienced research assistants with
higher vocational training in psychology will be trained
on the different sites in assessing patients for treatment
outcome measures. Study researchers, screeners, research
assistants and therapists are masked to treatment alloca-
tion during the screening period and the first assessment.
Table 1 summarizes the measures that are used at each
point.
The M.I.N.I. [32,33] will be used for assessing the Axis I
diagnosis. The BPD section of the Structured Clinical
Interview for the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) (SCID-II)
[28,29] will be used for assessing the diagnosis BPD. If
Antisocial Personality Disorder is suspected patients will
not be included. To assess the severity of the borderline
complaints patients will be screened using a semi struc-
tured clinical interview, the Borderline Personality Disor-
der Severity Index, fourth version (BPDSI-IV; range 0-90)
[30,31]. A BPDSI-IV cut off score of ≥ 20 discriminates
patients with BPD from patients with other personality
disorders [31]. Further, if illiteracy is suspected, the Dutch
Adult Reading Test [34] will be administered.
Outcome measures
Primary outcome measure
The primary outcome measure is the score on the BPDSI-
IV, a DSM-IV BPD criteria- based semi- structured inter-
view: this 70- item index represents the current severity
and frequency of the DSM-IV BPD manifestations. This
instrument shows excellent psychometric features (Cron-
bach's alpha = 0.85, interrater reliability, 0.99; validity
and sensitivity to change [30,31]. Previous research
[30,31] found a cut-off score [35] of 15 between patients
with BPD and controls, with a specificity of 0.97 and a
sensitivity of 1.00.
Recovery criterion
The recovery criterion is, therefore, defined as achieving a
BPDSI-IV score of less than 15 and maintaining this score
until the last assessment.
Reliable change
A second criterion is reliable change [35], which reflects
individual clinically significant improvement. For the
BPDSI-IV, reliable change is achieved when improvement
is at least 11.70 points at the last assessment [22].
Secondary outcome measures
EuroQol and WHOQol
Information on demographic factors (age, gender, marital
status, education and employment status) will be col-
lected at baseline. A secondary outcome measure is qual-
ity of life, which will be assessed by means of two widely
used and psychometrically sound self-report question-
naires: the EuroQol-thermometer and EQ-5D and the
World Health Organisation Quality of Life Questionnaire
[36-39]. The vertical EuroQol-thermometer rating indi-
cates one's experienced level between worst (0) and best
(100) imaginable health status. The EQ-5D contains 5
dimensions: mobility, self care, daily activities, pain/dis-
comfort and depression/anxiety. Each dimension is rated
at three levels: no problems, some problems and major
problems. EQ-5D health states can be converted into util-
ity scores ranging between -0.59 and 1, with higher utility
scores representing a better quality of life. The WHOQOL
is a 100-item self-report questionnaire, and through the
domains of physical health, psychological health, envi-
ronment, personal convictions, social relationships and
extent of independency, the WHO concept of quality of
life is assessed.
BPD-47, SCL-90, Young Schema Questionnaire
Other secondary outcome measures are measures for gen-
eral psychopathologic dysfunction and measures of ST
personality concepts, all in self-report format and with
robust psychometric properties. These measures include
the BPD Checklist on the burden of BPD-specific symp-
toms [40] and the Symptom Checklist-90 for subjective
experience of general psychopathology [41,42]. A theory
specific instrument is the Young Schema Questionnaire
on schemas underlying Young's theory [43-46].
Economic evaluation
In addition to the clinical evaluation, an economic evalu-
ation will be performed to assess the cost-effectiveness of
ST with versus ST without extra phone support outside
office hours. In the cost-effectiveness analysis of ST with
versus ST without phone support, the difference in costs
will be related to the difference in effectiveness, resulting
in an Incremental Cost Effectiveness Ratio (ICER). The
cost-effectiveness analysis will be based on two different
effectiveness outcomes. First, cost-effectiveness will be
based on the proportion of patients recovered according
to the BPDSI-IV, this reflecting the investment needed to
cure one patient. Secondly, cost-effectiveness will be
based on Quality Adjusted Life Years (QALY), which are
calculated with the EQ-5D utility scores, resulting in costs
per QALY. The cost-effectiveness analysis will be based on
the principles of a societal perspective using a time hori-Page 4 of 10
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cost-interview that will take place during the patient inter-
view alongside the other measurements. The cost-inter-
view contains items about paid and unpaid work, study,
daily activities, family burden, paid help, use of healthcare
and social services, use of medication, consumption of
alcohol and drugs and out-of-pocket expenses. Also the
number of face-to-face and telephone contacts with the
study therapists will be registered.
Therapeutic Alliance
This study will also investigate the quality and the devel-
opment of the therapeutic alliance as a mediator of
change in ST. In the RCT [1] scores for the therapeutic alli-
Table 1: Summary of measures
Measure Baseline 6 months 12 months 18 months Follow-up 36 months
Interview:
Mini International Neuropsychiatric Interview (MINI) x
Demographics x
Structured Clinical Interview for DSM-IV, axis II (SCID-II), section 
Borderline Personality Disorder
x
Borderline Personality Disorder Severity Index-IV (BPDSI-IV) x x x x x
(Dutch Adult Reading Test) x
Self report measures:
Borderline PersonalityDisorder-47 (BPD-47) x x x x x
Symptom Check List 90 (SCL-90) x x x x x
European Quality of Life (EuroQol) x x x x x
World Health Organization Quality of Life (WHOQol) x x x x x
Young Schema Questionnaire L 2 (YSQ) x x x x x
Questionnaire for economic evaluation:
Cost interview x x x x x
Questionnaires for therapeutic relationship:
Working Alliance Inventory, patient version (WAI-P) x x x x x
Questionnaire filled in by therapists:
Working Alliance Inventory, therapist version (WAI-T) x x x x x
Difficult Doctor Patient Relationship Questionnaire (DDPRQ) x x x x xPage 5 of 10
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therapists and patients at early treatment were predictive
of dropout, while increasingly positive ratings of patient
in the first half of treatment predicted subsequent clinical
improvement [47]. Therapeutic alliance will be measured
by the Working Alliance Inventory (WAI) and the Difficult
Doctor-Patient Relationship Questionnaire - Ten Item
Version (DDPRQ-10).
The WAI [48] is one of the most commonly used and
extensively validated measure of the alliance. It has been
found to predict therapy outcome in numerous studies
[49,50]. The Dutch version of the WAI consists of three
subscales of 12 items each, rated on a 5-point in stead of
7-point Likert-type scale ranging from 1 ("never") to 5
("always"). The subscales based on Bordin's [51] working
alliance theory address agreement about the goals of ther-
apy, agreement about the tasks of therapy, and the bond
between the client and therapist. Patients have to com-
plete the patient form (WAI-P) measuring the contribu-
tion of the therapist to the alliance as perceived by the
patient and therapists have to complete the therapist form
(WAI-T) in which they rate the contribution of the patient
to the alliance. Because of the high intercorrelations
among subscales (WAI-P range: .69 - .88; WAI-T range: .67
- .89) subscale mean scores are added together to derive a
global score. A higher score on the WAI indicates a higher
quality of the working alliance.
Difficult Doctor-Patient Relationship Questionnaire - Ten
Item Version (DDPRQ-10). The DDPRQ [52] is a self-
report questionnaire, which aims to measure the extent to
which patients are experienced as frustrating or difficult in
the therapeutic relationship by their doctor or therapist
and provoke levels of distress that transcend the expected
and accepted level of difficulty. Of the DDPRQ-10 five
items are about the therapist's subjective experience (e.g.,
"Do you find yourself secretly hoping that this patient will
not return?"), four are quasi-objective questions about the
patient's behavior (e.g., "How time consuming is caring
for this patient?"), and one item about symptoms com-
bines elements of the patient's behavior and the thera-
pist's subjective response (i.e. "To what extent are you
frustrated by this patient's vague complaints?"). The items
are answered on a 6-point Likert-type scale ranging from
1 ("not at all") to 6 ("a great deal"). The total score of the
DDPRQ equals the mean of the 10 items. A higher score
indicates a higher level of therapist frustration.
Treatment Adherence
Treatment adherence will be monitored by means of
supervision. All sessions will be audiotaped. The audio-
tapes will be saved for evaluation. Of all patients one
audiotape between 5 and 12 months of treatment will be
randomly selected. Twenty tapes will be rated by inde-
pendent raters to assess the intra class correlation coeffi-
cient (ICC). The raters will be independent of the study
and masked to treatment condition and outcome. The
raters will be psychologists trained in ST. We will use the
ST Therapy Adherence and Competence Scale for BPD
[53]. This instrument consists of visual analogue scales
and Likert scale items and has a competence cutoff score
of at least 60.
Registration of the phone contact
All therapists of the condition with phone support outside
office hours have to monitor the telephone contacts on
standardized forms with the following specifications:
duration of the contact (minutes), time (weekday/nights
or weekend), point of time (day, evening, night), reason
of the phone contact (crisis, therapeutic, administrative).
All contacts will be registered and used for calculating the
number of therapeutic and crisis contacts outside office
hours. The data will also be used for another yet to pub-
lish cost-outcome article.
Registration of therapy sessions
Therapists have to monitor the number of sessions. The
content of the sessions and the used ST-techniques have to
be registered on standardized forms.
Problems during the implementation process
These will be monitored by the researcher, recorded in a
log book, and discussed with the project group during
monthly meetings and with the therapists during the
monthly supervision. Possible topics that will be dis-
cussed are the experiences of therapists and research
assistants with the project, no show or drop-outs of
patients, support of therapists by management, peers, and
crisis facilities, and organizational changes influencing
the implementation process like reorganizations.
Implementation interventions
On the basis of explorations of possible facilitators and
barriers, the following implementation interventions will
be applied to enhance successful implementation [54].
Firstly, therapists, managers and assistants of different
mental healthcare centers will be informed of the study.
Secondly, agreements will be made with the therapists
and managers about the time investment for the treat-
ment protocol (sessions twice a week, peer supervision
weekly and supervision once a month) and financial
aspects. Thirdly, therapists and research assistants will be
trained and support on organizational level will be
offered. The process evaluation aims to assess the impact
of these implementation interventions on the delivery of
ST for BPD patients and to analyze the problems that may
occur during the implementation process.
Training and supervision
As the primary aim of the study is to assess whether ST can
be successfully implemented in regular mental healthcarePage 6 of 10
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pared to the Giesen-Bloo et al. trial. In the study of Giesen-
Bloo et al. [1] the ST therapists were trained and super-
vised by the originator of ST, Jeffrey Young, in the imple-
mentation study the therapists will be trained and
supervised by Dutch experts [55,56]. The training will be
based on a structured and piloted program supported by
a set of DVDs with examples of ST techniques, see Nadort
et al. [54].
Therapists will be trained in a 50 hours training program
(eight days during a period of two months). Essential to
the treatment is expert supervision and peer supervision.
During the first year monthly supervision will be provided
on each site, in the second year supervision will be pro-
vided every two months. The therapists will have weekly
peer supervision on each site. There will be a 1-day central
supervision for all therapists once a year.
Frequency of sessions and treatment period
In the RCT [1] the treatment period was three years with
sessions twice a week. In the implementation study there
will be sessions twice a week in the first year, but sessions
once a week in the second year. In the implementation
study we decided to do the first evaluation after a treat-
ment period of eighteen months. This was decided for sev-
eral reasons: different treatments have shown positive
results after 1-1,5 years of treatment [1,15,16,18], effec-
tiveness already became apparent after one year [1] and
most drop outs occurred during the first 1,5 years of ther-
apy [1,15].
Treatment Protocol
Treatment will be offered in 45-minutes sessions twice a
week in the first year and once a week in the second year.
Treatment protocols address the theoretical model, treat-
ment frame, different phases and the use of strategies and
techniques [11,13,14,55-58]. Central to ST is the assump-
tion of 5 schema modes specific for BPD. Schema modes
are sets of schemas expressed in pervasive patterns of
thinking, feeling and behaving [59,60]. Change is
achieved through a range of behavioral, cognitive and
experiential techniques that focus on (1) the therapeutic
relationship, (2) daily life outside therapy and (3) past
(traumatic) experiences. Recovery in ST is achieved when
dysfunctional schemas no longer control or rule the
patient's life.
Sample size and Data Analysis
Sample size
The BPDSI-IV power calculation is based on the aim of
showing a difference at the patient level between the con-
ditions with extra phone support of the therapist outside
office hours versus the condition without such support.
Because we do not know what the effect of the extra phone
support is, it is decided to use a medium effect size of 0.5,
according to Cohen [61], for the power calculation. With
a minimum of 2 × 30 patients per condition, the power to
demonstrate such a difference between the two conditions
with two-tailed alpha of 0.05 is 84. Therefore a minimum
of 60 patients is required and accordingly 30 therapists
need to be recruited.
Analysis
The statistical analyses will be based on the intention-to-
treat as randomized principle. Treatment effects will be
tested with survival analysis for dichotomous variables,
and one-sample t-tests and ANCOVAs for continuous var-
iables with baseline as covariate and condition as between
group factor. When no deviations from distributional
assumptions are detected, parametric ANCOVAs will be
used.
Using Cohen's formula, effect sizes will be calculated as
X1-X2/SDpooled, were X1 represents the pre-treatment
scores, X2 the post-treatment scores, and SDpooled repre-
sents the pooled standard deviations of the pre- and post-
treatment scores.
All the tests will be two-tailed with a significance level of
5%. Analyses will be performed using the Statistical Pack-
age for Social Sciences, version 15.0 for Windows (sur-
vival analyses, within-group analyses, Chi-square tests).
In the RCT [1] a pre to post treatment effect size difference
of d = 1.24 (Cohen's d) was found on the main patient
outcome measure BPDSI on 18 months. In the present
study, the same treatment will be less intensive and exe-
cuted in non-academic practice, so that a lower effective-
ness can be expected. We therefore tentatively estimate the
pre-post difference as d = 1.0.
It will be concluded that extra crisis support is definitely
helpful if at the patient level a medium effect difference is
found between the conditions with and without extra
phone support. A possible small difference in effect will,
although indicating that the extra support is helpful,
probably not convince clinicians to implement this extra
availability in their regular practice.
For the economic evaluation, analysis will also be per-
formed according to intention-to-treat principle. The
uncertainty around the cost-effectiveness and cost-utility
ratios will be analyzed using bootstrapping techniques.
Results of these bootstraps will be presented in cost-effec-
tiveness planes
(showing all bootstrapped cost-effectiveness combina-
tions) and cost-effectiveness acceptability curves (CEACs)
which represent the probability that the intervention is
cost-effective, given a certain threshold for the costs per
unit of effect gained.Page 7 of 10
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The participation in the study is voluntary. Participants
are informed that they can cancel their participation at
any time without disclosing reasons for their cancellation
and without negative consequences for their future care.
Participants will sign an informed consent.
Vote of the ethics committee
The design and conduct of the study was approved by the
Medical Ethics Committee for General Mental Healthcare
(METIGG 5230).
Discussion
This study protocol is presented here to offer researchers
the opportunity to consider the methodological quality of
this study with a critical view. Therapists can benefit by
considering the information regarding the practical appli-
cations of the proposed protocol on borderline patients in
secondary care. The number of studies on ST for BPD is
small, while BPD affects a large group of patients in regu-
lar mental healthcare. Research into the effectiveness of ST
when it is implemented in regular mental healthcare can
make an important contribution to the improvement of
care for BPD patients. Also research into the added value
of phone support outside office hours provided by the
therapist can make an important contribution to the
application of ST.
Strengths and limitations
Many methodological requirements for a high quality
trial are met. Allocation is concealed through randomiza-
tion by an external researcher. Recruitment of the patients
will be done after the standard intake procedure at each
site. As this study takes place within different general men-
tal healthcare departments located in different parts of the
Netherlands the results can, to a large extent, be general-
ized to the population of borderline patients seen in reg-
ular mental healthcare in the Netherlands. A limitation of
the present study is that the assessments will be performed
by research assistants who cannot remain blinded to the
treatment condition of the included patients, as is always
the case in trials studying the effects of psychotherapy.
Nor are the patients blind to treatment condition. In this
study, however, added to the main interview-based out-
come measures, self-report questionnaires will be admin-
istered, that will not be influenced by the research
assistants.
Another limitation is the power of this study. This imple-
mentation study is powered to demonstrate a medium or
higher effect of TTA. The failure to detect any difference
between conditions, does not mean that they are equiva-
lent, only that differences, if any, will be small. A small
difference however does not imply lack of clinical signifi-
cance. But to detect a small effect with a significance level
of .05 and a power of 80, a power analysis shows that a
sample of more than 3100 patients is necessary, which is
not feasible for a trial on long-lasting psychotherapy.
Timeframe of the study
In December 2005 the randomized treatment study has
been started up.
Month 1-6: Recruitment of departments, therapists and
research assistants.
Month 6-8: Training of therapists and research-assistants.
Month 9-21: Screening and inclusion of borderline
patients at the different locations. Start of the data collec-
tion for the treatment study. Supervision of the treat-
ments. Start of data entry and purging of databases.
Month 27-43: Completion of data collection. Completion
of purging and analysis of the data. Publication on the
short-term findings.
Month 43 until 2010 Three-year follow-up assessments.
Publication on the (cost-)effectiveness of ST. Dissemina-
tion of the results (e.g. presentation of study results at
national and international conferences). Working on the
implementation of ST in the Netherlands.
Description of risks
There are no specific risks related to this study.
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